S Giovannini1, M Cesari, E Marzetti, C Leeuwenburgh, M Maggio, M Pahor. 1. Dept. of Aging and Geriatric Research, Division of Biology of Aging, University of Florida, Institute on Aging, 1600 SW Archer Road, PO Box 100143, Gainesville, FL 32610, USA. silvia_giovannini@yahoo.it
Abstract
OBJECTIVES: The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. DESIGN: Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial. SETTING:Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC. PARTICIPANTS: Subjects > or = 55 years old with high cardiovascular disease risk profile. INTERVENTION: The intervention consisted of 6-month administration of fosinopril vs. placebo. MEASUREMENTS: Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired ttests. RESULTS:The mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported. CONCLUSIONS: A six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance.
RCT Entities:
OBJECTIVES: The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. DESIGN: Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial. SETTING:Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC. PARTICIPANTS: Subjects > or = 55 years old with high cardiovascular disease risk profile. INTERVENTION: The intervention consisted of 6-month administration of fosinopril vs. placebo. MEASUREMENTS: Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired ttests. RESULTS: The mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported. CONCLUSIONS: A six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance.
Authors: A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi Journal: J Endocrinol Invest Date: 2005-05 Impact factor: 4.256
Authors: Matteo Cesari; Stephen B Kritchevsky; Hal H Atkinson; Brenda W Penninx; Mauro Di Bari; Russell P Tracy; Marco Pahor Journal: Am Heart J Date: 2009-02 Impact factor: 4.749
Authors: Richard M Martin; David Gunnell; Elise Whitley; Andrew Nicolaides; Maura Griffin; Niki Georgiou; George Davey Smith; Shah Ebrahim; Jeff M P Holly Journal: J Clin Endocrinol Metab Date: 2008-01-22 Impact factor: 5.958
Authors: Gail A Laughlin; Elizabeth Barrett-Connor; Michael H Criqui; Donna Kritz-Silverstein Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: M Maggio; F Lauretani; F De Vita; V Buttò; C Cattabiani; S Masoni; E Sutti; G Bondi; E Dall'aglio; S Bandinelli; A Corsonello; A M Abbatecola; F Lattanzio; L Ferrucci; G P Ceda Journal: J Nutr Health Aging Date: 2014-04 Impact factor: 4.075
Authors: Thomas W Buford; Stephen D Anton; Anthony A Bavry; Christy S Carter; Michael J Daniels; Marco Pahor Journal: Contemp Clin Trials Date: 2015-06-23 Impact factor: 2.226
Authors: Tadashi Yoshida; A Michael Tabony; Sarah Galvez; William E Mitch; Yusuke Higashi; Sergiy Sukhanov; Patrice Delafontaine Journal: Int J Biochem Cell Biol Date: 2013-06-13 Impact factor: 5.085
Authors: Maha Sellami; Wissem Dhahbi; Lawrence D Hayes; Johnny Padulo; Fatma Rhibi; Hanen Djemail; Anis Chaouachi Journal: PLoS One Date: 2017-08-11 Impact factor: 3.240